Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle.
Barrera J, Brake DA, Kamicker BJ, Purcell C, Kaptur R Jr, Schieber T, Lechtenberg K, Miller TD, Ettyreddy D, Brough DE, Butman BT, Colby M, Neilan JG. Barrera J, et al. Among authors: butman bt. Transbound Emerg Dis. 2018 Apr;65(2):447-455. doi: 10.1111/tbed.12724. Epub 2017 Oct 27. Transbound Emerg Dis. 2018. PMID: 29076657 Free article.
Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge.
Schutta C, Barrera J, Pisano M, Zsak L, Grubman MJ, Mayr GA, Moraes MP, Kamicker BJ, Brake DA, Ettyreddy D, Brough DE, Butman BT, Neilan JG. Schutta C, et al. Among authors: butman bt. Vaccine. 2016 Jun 8;34(27):3214-3220. doi: 10.1016/j.vaccine.2015.12.018. Epub 2015 Dec 18. Vaccine. 2016. PMID: 26707216 Free article.
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine.
Barrera J, Brake DA, Schutta C, Ettyreddy D, Kamicker BJ, Rasmussen MV, Bravo de Rueda C, Zurita M, Pisano M, Hurtle W, Brough DE, Butman BT, Harper BG, Neilan JG. Barrera J, et al. Among authors: butman bt. Vaccine. 2018 Nov 19;36(48):7345-7352. doi: 10.1016/j.vaccine.2018.10.031. Epub 2018 Oct 13. Vaccine. 2018. PMID: 30327212 Free article.
Comprehensive characterization of the 293-ORF6 cell line.
Butman BT, Lizonova A, Brough DE, Sowers JM, Sheets R, Gall J, Newton P, Gomez P. Butman BT, et al. Dev Biol (Basel). 2006;123:225-33; discussion 265-6. Dev Biol (Basel). 2006. PMID: 16566448 No abstract available.
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, Butman BT, Gall JG, King CR, Andrews CA, Sheets R, Gomez PL, Mascola JR, Nabel GJ, Graham BS; Vaccine Research Center 006 Study Team. Catanzaro AT, et al. Among authors: butman bt. J Infect Dis. 2006 Dec 15;194(12):1638-49. doi: 10.1086/509258. Epub 2006 Nov 8. J Infect Dis. 2006. PMID: 17109335 Free PMC article. Clinical Trial.
23 results